永赢医药创新智选混合发起C(015916)利润分配表
|
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
收入 |
464,177,216.05 |
-37,637,062.23 |
-61,431,028.91 |
-27,766,422.43 |
利息合计 |
413,759.64 |
104,677.04 |
66,286.34 |
90,165.28 |
其中:存款利息收入 |
413,759.64 |
104,677.04 |
66,286.34 |
88,258.54 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
1,906.74 |
投资收益合计 |
78,471,420.78 |
-46,411,293.94 |
-51,353,371.68 |
-28,298,077.93 |
其中:股票投资收益 |
75,894,669.60 |
-47,383,322.70 |
-52,123,425.57 |
-28,784,509.38 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
29,689.91 |
45,335.50 |
376.11 |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
2,547,061.27 |
926,693.26 |
769,677.78 |
486,431.45 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
359,402,831.64 |
6,977,661.80 |
-10,899,151.57 |
-1,280,220.65 |
其他收入 |
25,889,203.99 |
1,691,892.87 |
755,208.00 |
1,721,710.87 |
费用 |
9,390,824.33 |
3,816,536.59 |
2,027,374.75 |
2,934,009.85 |
管理人报酬 |
6,936,637.44 |
2,738,389.82 |
1,451,828.12 |
2,079,375.69 |
基金托管费 |
289,026.56 |
114,099.52 |
60,492.73 |
86,640.70 |
销售服务费 |
2,065,627.91 |
797,982.83 |
422,999.06 |
589,797.47 |
交易费用 |
- |
- |
- |
- |
利息支出 |
2,042.78 |
1,135.92 |
- |
- |
其中:卖出回购金融资产支出 |
2,042.78 |
1,135.92 |
- |
- |
其他费用 |
97,489.64 |
164,928.50 |
92,054.84 |
178,195.99 |
利润总额 |
454,786,391.72 |
-41,453,598.82 |
-63,458,403.66 |
-30,700,432.28 |